Risk Factors and the Effect of Plasma Exchange on Prognosis of Pregnancy-related Thrombotic Microangiopathies

Study Overview
=================
Brief Summary
-----------------
Early identification of the risk factors of pregnancy-related thrombotic microangiopathies can help us reduce the complications of such patients and increase the survival rate of patients. In addition, it is still controversial whether patients with pregnancy-related thrombotic microvessels should receive plasma therapy.

Detailed Description
-----------------
Objective: To evaluate the risk factors of pregnancy-related thrombotic microangiopathies and the effect of plasma exchange on the prognosis (recovery status of renal function, recovery status of platelets, survival or death within 28 days). Design: A retrospective analysis of pregnant patients admitted to the ICU from 2015 to 2019. According to the outcome indicator of the occurrence of pregnancy-related thrombotic microangiopathies, they were divided into thrombotic microangiopathies group and non-thrombotic microangiopathies group. Patients in the pregnancy-related thrombotic microangiopathy group were divided into plasma exchange combined non-plasma exchange group according to whether they received plasma exchange. Collect the clinical data of the patients, and analyze the data using SPSS 1 7.0 statistical software package. The measurement data were compared by paired t test and one-way analysis of variance; the count data were compared by χ2 test. Compare the differences of the indicators between the two groups and analyze the risk factors of pregnancy-related thrombotic microangiopathies. Then compare whether there is a difference in the prognosis between the plasma exchange group and the non-plasma exchange group.

Official Title
-----------------
Risk Factors for Pregnancy-related Thrombotic Microangiopathies Retrospective Study of the Effect of Plasma Exchange on Prognosis of Pregnancy-related Thrombotic Microangiopathies

Conditions
-----------------
Pregnancy-related Thrombotic Microangiopathies

Intervention / Treatment
-----------------
* Device: plasma exchange


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pregnant patients admitted to the Department of critical care medicine, the Third Hospital of Peking University from 2015 to 2019 Exclusion Criteria: NO
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No TMA<br>parturients without thrombotic microangiopathies | Device: plasma exchange<br>* Plasma exchange was performed daily for five times or until platelet level returned to normal<br>|
| TMA with plasma exchange<br>parturients with thrombotic microangiopathies, and treated with plasma exchange | Device: plasma exchange<br>* Plasma exchange was performed daily for five times or until platelet level returned to normal<br>|
| TMA without plasma exchange<br>parturients with thrombotic microangiopathies, but not treated with plasma exchange | Device: plasma exchange<br>* Plasma exchange was performed daily for five times or until platelet level returned to normal<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| TMA happen | pregnancy associated thrombotic microangiopathy happen or not at 28th day after ICU admission | 28th day after ICU admission | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| renal function | renal function at 28th day after ICU admission | 28th day after ICU admission | 
| platelet level | platelet level at 28th day after ICU admission | 28th day after ICU admission | 
| survival rate | survival rate at 28th day after ICU admission | 28th day after ICU admission | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pregnancy, thrombotic microangiopathies